Jan Basile to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Jan Basile has written about Angiotensin-Converting Enzyme Inhibitors.
Connection Strength
1.119
-
Lessons learned from the ONTARGET and TRANSCEND trials. Curr Atheroscler Rep. 2009 Sep; 11(5):371-6.
Score: 0.301
-
Fixed-dose combination therapy in the treatment of hypertension: ready for prime time. South Med J. 2007 Apr; 100(4):343-4.
Score: 0.254
-
Halting the progression of heart failure: finding the optimal combination therapy. Cleve Clin J Med. 2002 Feb; 69(2):104-5, 109-10, 112.
Score: 0.178
-
Aspirin and angiotensin-converting enzyme inhibitors are safe when taken together after acute myocardial infarction in patients with left ventricular dysfunction. J Clin Hypertens (Greenwich). 2001 Nov-Dec; 3(6):376-7.
Score: 0.175
-
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2008 Oct; 10(10):751-60.
Score: 0.071
-
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep; 48(3):374-84.
Score: 0.061
-
Analysis of recent papers in hypertension. J Clin Hypertens (Greenwich). 2004 Feb; 6(2):96-101.
Score: 0.051
-
Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):42-50.
Score: 0.019
-
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2001 Apr; 24(4):654-8.
Score: 0.010